ClinicalTrials.gg
TerminatedNCT02010203Updated Feb 17, 2020Results posted

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

A Phase 1/2 interventional study of HS-410 and Placebo in Bladder Cancer, sponsored by Heat Biologics. Terminated at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-17.

Sponsored by Heat Biologics · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Inability to accrue due to changing treatment landscape (PD-1 approvals)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms — 3 open to participants now, 8 under way, 4 of them phase 3. BCG Vaccine · Urinary Bladder Neoplasms.

Enrollment
11th of 20
104 · median 112
Started
2013
with 2 others
Phase 1/2
4 of 20
none open now
Registered
5th of 20
by date
Lead sponsor
1 of 20
Heat Biologics

Among the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms, this one is the 11th largest by enrollment, is one of 3 that started in 2013, is one of 4 in phase 1/2, and was the 5th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

3 of the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About BCG Vaccine

BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

Phase I/II study: Phase 1 is an open-label, safety study, patients who previously received 3-6 instillations of weekly intravesical Bacillus Calmette-Guerin (BCG) induction therapy (as standard of care) followed by low dose intradermal (1*10\^6 cells) HS-410 monotherapy. Phase 2, patients will be randomized to one of three blinded (physician-patient), placebo-controlled groups and receive either intradermal placebo or low dose (1*10\^6 cells) or high dose (1*10\^7 cells) vesigenurtacel-L in combination with induction and maintenance intravesical BCG. Patients who do not receive BCG will be enrolled into an open-label, non-randomized group receiving high dose (1*10\^7 cells) intradermal HS-410 monotherapy.

Read the detailed description

This study is a two part study: Phase I and Phase II. The Phase 1 portion is an open-label, safety study. Patients will have previously received 3-6 instillations of weekly intravesical Bacillus Calmette-Guerin (BCG) induction therapy (as standard of care) followed by low dose intradermal (1*10\^6 cells) HS-410 monotherapy. In Phase 2, patients will be assigned to treatment groups based on whether they will receive induction BCG in the typical post-TURBT window. If the investigator plans to administer BCG, patients will be randomized to one of three blinded (physician-patient), placebo-controlled groups and receive either intradermal placebo or low dose (1*10\^6 cells) or high dose (1*10\^7 cells) vesigenurtacel-L in combination with induction and maintenance intravesical BCG. If patients will not receive BCG, they will be enrolled into an open-label, non-randomized group and receive high dose (1*10\^7 cells) intradermal HS-410 monotherapy.

03

Conditions studied

  • Bladder Cancer

Keywords

  • TURBT
  • Bladder
  • Cancer
  • GP96
  • Vaccine
  • Immunotherapy
  • Heat Biologics
  • BCG
  • Bacillus Calmette-Guerin
  • Bacillus Calmette-Guérin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed non-muscle invasive bladder cancer [Ta, T1 or Tis (CIS)] that has been removed by transurethral resection
  • Either: (i) high-risk disease, defined as T1 and/or high-grade and/or CIS or (ii) intermediate-risk disease, defined as Ta low-grade with at least 3 of the following 4 risk factors: multiple tumors, tumor size > 3cm, early recurrence (\<1 year from previous staging procedure), or recurrence with a frequency of more than once in any 12 month period
  • Not have received bacillus Calmette-Guérin (BCG) or have completed previous BCG treatment > 12 months prior to the baseline staging procedure.
  • Phase 2 Arms 1-3: Suitable to receive a 6-week course of BCG in the setting within 6 weeks following TURBT. Phase 2 Arm 4: Suitable for monotherapy vaccine administration post-TURBT. For Phase 1 only: Has previously received 3-6 weekly doses of BCG.
  • Adequate laboratory parameters

Exclusion criteria

Exclusion Criteria:

  • (HIV) infection or immunodeficiency disorders, either primary or acquired
  • Infections or intercurrent illness requiring active therapy
  • Any condition requiring active or other therapy
  • Active within the past 12 months except negligible risk of or death treated with expected curative outcome.
  • Prostate pelvic radiation within the past 12 months
  • Significant cardiac impairment
  • Current alcohol or chemical abuse, or mental or psychiatric condition precluding protocol compliance
  • Pregnant or nursing
  • Allergy to soy, egg, or peanut products
  • Receiving another agent (30 day wash-out required prior to first dose)
  • therapy prior to baseline staging procedures for the current occurrence of non-muscle invasive bladder cancer
  • Prior treatment with a cancer vaccine for this indication
  • Prior vaccination with BCG for tuberculosis disease
  • Prior splenectomy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Phase I: HS-410 Low Dose

    In the open label Phase 1 portion, HS-410 is given as 1\*10\^6 cells per dose for 12 weekly injections followed by 3 monthly injections.

    Biological: HS-410

  • Experimental
    Phase II: HS-410 Low-Dose Plus BCG

    In the Phase 2 portion, HS-410 is given as 1\*10\^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.

    Biological: HS-410 · Biological: BCG

  • Experimental
    Phase II: High-Dose HS-410 Plus BCG

    In the Phase 2 portion, HS-410 is given as 1\*10\^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.

    Biological: HS-410 · Biological: BCG

  • Placebo comparator
    Phase II: Placebo Plus BCG

    In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.

    Biological: Placebo · Biological: BCG

  • Experimental
    Phase II: High-Dose HS-410

    In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1\*10\^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.

    Biological: HS-410

Interventions

  • BiologicalHS-410

    Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96

  • BiologicalPlacebo

    Injection containing sterile solution but no cells

  • BiologicalBCG

    Vaccine derived from a live bacterium

    Also known as: Bacillus Calmette-Guerin

06

What researchers measure

Primary outcomes

  1. Phase 1: Safety and Tolerability

    To evaluate the safety and tolerability of vesigenurtacel-L

    Time frame: Up to 3 years.

  2. Phase 2: 1-year Disease-Free Survival

    Arm 1, 2, 3: 1-year DFS in patients with NMIBC treated with BCG in combination with blinded study product (one of two doses of vesigenurtacel-L or placebo) Arm 4: 1-year DFS in patients with NMIBC treat1fv 9 with high dose vesigenurtacel-L monotherapy One-year disease-free survival will be defined as the proportion of patients who are free from recurrent disease, progressive disease, and alive one year after the date of randomization/treatment assignment

    Time frame: One year

Secondary outcomes

  1. Proportion of Patients With Recurrence at 3, 6, 12, 18, and 24 Months

    Evaluate the proportion of patients with recurrence at 3, 6, 12, 18, and 24 months

    Time frame: Up to 2 years

  2. Proportion of Patients With Progressive Disease at 3, 6, 12, 18, and 24 Months

    Evaluate the proportion of patients with progressive disease at 3, 6, 12, 18, and 24

    Time frame: Up to 2 years

  3. Disease-free Survival at 3, 6, 18, and 24 Months

    Evaluate Disease Free Survival at 3, 6, 18 and 24 months

    Time frame: Up to 2 years

  4. Overall Disease-free Survival

    Evaluate overall Disease Free Survival

    Time frame: Up to 3 years

  5. Overall Survival, Expressed as the Number of Participants Alive

    Evaluate overall survival (OS)

    Time frame: Up to 3 years

  6. Proportion of Patients Undergoing Repeat Transurethral Resection of Bladder Tumor (TURBT) by 12 and 24 Months

    Time frame: Up to 2 years

  7. Proportion of Patients Undergoing Cystectomy by 12 and 24 Months

    Evaluate the proportion of patients undergoing cystectomy by 12 and 24 months from randomization

    Time frame: Up to 2 years

  8. Immunologic Response of PBMCs Via Intracellular Cytokine Staining (ICS) by Flow Cytometry and/or Enzyme-linked Immunosorbent Spot (ELISPOT) on CD8+ Cells After HS-410 Vaccination as Compared to Baseline.

    Evaluate the proportion of patients with immunologic response of peripheral blood mononuclear cells (PBMCs) via intracellular cytokine staining (ICS) by flow cytometry and/or ELISPOT on CD8+ cells following vesigenurtacel-L vaccination

    Time frame: Up to 2 years

  9. Immunologic Response of Peripheral Blood Mononuclear Cells (PBMCs) and Stimulation Analysis Via ICS in Baseline and Post-treatment Biopsies, if Clinically Indicated

    Evaluate immunologic response of PBMCs (analysis of surface markers, CD3, CD4, CD8, CD19, CD25, CD45, CD56, FoxP3, and degranulation) and stimulation analysis via ICS of interferon gamma (IFNγ) and granzyme B (gzB)

    Time frame: Up to 3 years

  10. Total PBMC Counts by Flow Cytometry

    Evaluate total PBMC counts by flow cytometry, including lymphocyte subsets (B cells, helper T-cells, cytotoxic T-cells, natural killer (NK) cells and T-reg)

    Time frame: Up to 3 years

  11. Tumor Antigen Expression

    Evaluation of pre-treatment tumor tissue for antigen expression

    Time frame: At screening

  12. Tumor Infiltrating Lymphocytes (TILs)

    Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs

    Time frame: Up to 3 years

  13. T Cell Receptor Sequencing of Peripheral Blood T Cells Before and During Treatment

    Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs, T cell receptor sequencing of peripheral blood T cells before and during the course of treatment.

    Time frame: Up to 2 years

  14. Safety of the Combination of the HS-410 and BCG

    Phase 2 only Evaluate the safety of the combination of vesigenurtacel-L and BCG

    Time frame: Up to 1 year

  15. Safety of the High Dose HS-410 Monotherapy

    Phase 2 only Evaluate the safety of high dose vesigenurtacel-L monotherapy

    Time frame: Up to 3 years.

07

Results

Posted Feb 17, 2020

Participant flow

Participant flow — Overall Study
MilestonePhase I: HS-410 Low DosePhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410
Started1026262616
Completed101716233
Not completed0910313

Outcome measures

PrimaryPhase 1: Safety and Tolerability

To evaluate the safety and tolerability of vesigenurtacel-L

Time frame:
Up to 3 years.
Reported as:
Count of participants · Participants
Phase 1: Safety and Tolerability
ParticipantsPhase I: HS-410 Low Dose
Gastrointestinal Disorders3
General Disorders & Administration Site Conditions5
Musculoskeletal & Connective Tissue Disorders1
PrimaryPhase 2: 1-year Disease-Free Survival

Arm 1, 2, 3: 1-year DFS in patients with NMIBC treated with BCG in combination with blinded study product (one of two doses of vesigenurtacel-L or placebo) Arm 4: 1-year DFS in patients with NMIBC treat1fv 9 with high dose vesigenurtacel-L monotherapy One-year disease-free survival will be defined as the proportion of patients who are free from recurrent disease, progressive disease, and alive one year after the date of randomization/treatment assignment

Time frame:
One year
Reported as:
Count of participants · Participants
Phase 2: 1-year Disease-Free Survival
ParticipantsPhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410
Phase 2: 1-year Disease-Free Survival79612
SecondaryProportion of Patients With Recurrence at 3, 6, 12, 18, and 24 Months

Evaluate the proportion of patients with recurrence at 3, 6, 12, 18, and 24 months

Time frame:
Up to 2 years
Reported as:
Number · participants
Proportion of Patients With Recurrence at 3, 6, 12, 18, and 24 Months
participantsPhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410
3 months22192314
6 months1919229
12 months1817214
18 months1816152
24 months1414121
SecondaryProportion of Patients With Progressive Disease at 3, 6, 12, 18, and 24 Months

Evaluate the proportion of patients with progressive disease at 3, 6, 12, 18, and 24

Time frame:
Up to 2 years
Reported as:
Number · participants
Proportion of Patients With Progressive Disease at 3, 6, 12, 18, and 24 Months
participantsPhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410
3 Months1100
6 Months2303
12 Months2313
18 Months2324
24 Months2324
SecondaryDisease-free Survival at 3, 6, 18, and 24 Months

Evaluate Disease Free Survival at 3, 6, 18 and 24 months

Time frame:
Up to 2 years
Reported as:
Number · participants
Disease-free Survival at 3, 6, 18, and 24 Months
participantsPhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410
3 months22192314
6 months1919229
12 months1817214
18 months1716152
24 months1314121
SecondaryOverall Disease-free Survival

Evaluate overall Disease Free Survival

Time frame:
Up to 3 years
Reported as:
Number · participants
Overall Disease-free Survival
participantsPhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410
Overall Disease-free Survival1817183
SecondaryOverall Survival, Expressed as the Number of Participants Alive

Evaluate overall survival (OS)

Time frame:
Up to 3 years
Reported as:
Number · participants
Overall Survival, Expressed as the Number of Participants Alive
participantsPhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410
Overall Survival, Expressed as the Number of Participants Alive26262616
SecondaryProportion of Patients Undergoing Repeat Transurethral Resection of Bladder Tumor (TURBT) by 12 and 24 Months
Time frame:
Up to 2 years
Reported as:
Number · participants
Proportion of Patients Undergoing Repeat Transurethral Resection of Bladder Tumor (TURBT) by 12 and 24 Months
participantsPhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCG
12 Month8610
24 Months8711
SecondaryProportion of Patients Undergoing Cystectomy by 12 and 24 Months

Evaluate the proportion of patients undergoing cystectomy by 12 and 24 months from randomization

Time frame:
Up to 2 years
Reported as:
Number · participants
Proportion of Patients Undergoing Cystectomy by 12 and 24 Months
participantsPhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410
12 Months0001
24 Months1001
SecondaryImmunologic Response of PBMCs Via Intracellular Cytokine Staining (ICS) by Flow Cytometry and/or Enzyme-linked Immunosorbent Spot (ELISPOT) on CD8+ Cells After HS-410 Vaccination as Compared to Baseline.

Evaluate the proportion of patients with immunologic response of peripheral blood mononuclear cells (PBMCs) via intracellular cytokine staining (ICS) by flow cytometry and/or ELISPOT on CD8+ cells following vesigenurtacel-L vaccination

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondaryImmunologic Response of Peripheral Blood Mononuclear Cells (PBMCs) and Stimulation Analysis Via ICS in Baseline and Post-treatment Biopsies, if Clinically Indicated

Evaluate immunologic response of PBMCs (analysis of surface markers, CD3, CD4, CD8, CD19, CD25, CD45, CD56, FoxP3, and degranulation) and stimulation analysis via ICS of interferon gamma (IFNγ) and granzyme B (gzB)

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondaryTotal PBMC Counts by Flow Cytometry

Evaluate total PBMC counts by flow cytometry, including lymphocyte subsets (B cells, helper T-cells, cytotoxic T-cells, natural killer (NK) cells and T-reg)

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondaryTumor Antigen Expression

Evaluation of pre-treatment tumor tissue for antigen expression

Time frame:
At screening

No measurements were reported for this outcome.

SecondaryTumor Infiltrating Lymphocytes (TILs)

Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondaryT Cell Receptor Sequencing of Peripheral Blood T Cells Before and During Treatment

Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs, T cell receptor sequencing of peripheral blood T cells before and during the course of treatment.

Time frame:
Up to 2 years

No measurements were reported for this outcome.

SecondarySafety of the Combination of the HS-410 and BCG

Phase 2 only Evaluate the safety of the combination of vesigenurtacel-L and BCG

Time frame:
Up to 1 year

No measurements were reported for this outcome.

SecondarySafety of the High Dose HS-410 Monotherapy

Phase 2 only Evaluate the safety of high dose vesigenurtacel-L monotherapy

Time frame:
Up to 3 years.

No measurements were reported for this outcome.

Adverse events

Collected over AEs were defined as all reported events with a start date on or after Study Day 1. All AEs were collected through 30 days post last dose, up to 3 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I: HS-410 Low Dose0/10 (0%)0/10 (0%)7/10 (70%)
Phase II: HS-410 Low-Dose Plus BCG0/26 (0%)8/26 (30.8%)24/26 (92.3%)
Phase II: High-Dose HS-410 Plus BCG0/26 (0%)4/26 (15.4%)19/26 (73.1%)
Phase II: Placebo Plus BCG0/26 (0%)1/26 (3.8%)20/26 (76.9%)
Phase II: High-Dose HS-4100/16 (0%)2/16 (12.5%)9/16 (56.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPhase I: HS-410 Low DosePhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410
Urinary Tract InfectionInfections and infestations0/102/260/260/260/16
Urinary RetentionRenal and urinary disorders0/100/260/260/261/16
Bladder PerforationRenal and urinary disorders0/100/260/260/261/16
CystoprostatectomyRenal and urinary disorders0/101/260/260/260/16
HypoxiaRespiratory, thoracic and mediastinal disorders0/101/260/260/260/16
Prostate CancerMusculoskeletal and connective tissue disorders0/101/260/261/260/16
PyrexiaGeneral disorders0/101/260/260/260/16
AneurysmVascular disorders0/101/260/260/260/16
Transient Ischaemic AttackNervous system disorders0/101/260/260/260/16
Mental Status ChangesPsychiatric disorders0/101/260/260/260/16
Most frequent other events
Showing 10 of 64
Most frequent other events
EventPhase I: HS-410 Low DosePhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410
Injection Site PainGeneral disorders4/100/260/260/260/16
FatigueGeneral disorders0/1010/266/264/263/16
DysuriaRenal and urinary disorders0/103/266/269/260/16
Urinary Tract InfectionInfections and infestations1/108/263/266/260/16
DiarrhoeaGastrointestinal disorders3/100/264/260/260/16
NauseaGastrointestinal disorders0/101/266/261/260/16
HaematuriaRenal and urinary disorders0/106/265/263/260/16
VomitingGastrointestinal disorders0/102/265/260/260/16
ChillsGeneral disorders0/105/264/263/260/16
PyrexiaGeneral disorders0/105/263/263/260/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase I: HS-410 Low DosePhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410Total
<=18 years000000
Between 18 and 65 years17126127
>=65 years91914201577
Age, Continuous
Age, Continuous(years)Phase I: HS-410 Low DosePhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410Total
Mean73.2 ± 7.49570.5 ± 11.17668.58 ± 11.51870.58 ± 9.04772.50 ± 9.78470.60 ± 10.172
Sex: Female, Male
Sex: Female, Male(Participants)Phase I: HS-410 Low DosePhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410Total
Female1356318
Male92321201386
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase I: HS-410 Low DosePhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410Total
Hispanic or Latino012205
Not Hispanic or Latino102524241699
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I: HS-410 Low DosePhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410Total
American Indian or Alaska Native000000
Asian001001
Native Hawaiian or Other Pacific Islander000000
Black or African American000202
White1026252316100
More than one race000000
Unknown or Not Reported000101
Region of Enrollment
Region of Enrollment(participants)Phase I: HS-410 Low DosePhase II: HS-410 Low-Dose Plus BCGPhase II: High-Dose HS-410 Plus BCGPhase II: Placebo Plus BCGPhase II: High-Dose HS-410Total
United States1026262616104
08

Study locations

19 sites
  • University of California at Los Angeles
    Los Angeles, California 90095, United States
  • Skyline Urology
    Sherman Oaks, California 91411, United States
  • Skyline Urology
    Torrance, California 90505, United States
  • Urology Center of Colorado
    Denver, Colorado 80211, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • First Urology
    Jeffersonville, Indiana 47130, United States
  • Horizon Oncology Research
    Lafayette, Indiana 47905, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • University of Massachusetts
    Worcester, Massachusetts 01655, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Montefiore Medical Center
    Bronx, New York 10471, United States
  • University of North Carolina Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Urology of North Texas
    Dallas, Texas 75231, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Urology of Virginia
    Virginia Beach, Virginia 23462, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Dec 2017 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2020, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2013
First posted
Dec 12, 2013
Start
Dec 2013
Primary completionActual
Dec 2017
CompletionActual
Apr 2018
Results first posted
Feb 17, 2020
Last update
Feb 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02010203
Lead sponsor
Heat Biologics
Responsible party
Sponsor
First posted
Dec 12, 2013
Start date
Dec 2013
Primary completion
Dec 2017
Completion
Apr 2018
Results posted
Feb 17, 2020
Last update
Feb 17, 2020

Study contacts

Gary Steinberg, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCG Vaccine

Start the discussion